bobbybobby
MarketsStocksJoin Us

The Ensign Group, Inc.

ENSG

$173.54

-3.93%

The Ensign Group, Inc. is a leading provider of post-acute healthcare services in the United States, operating skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care facilities through its regional subsidiaries. The company distinguishes itself through a decentralized operating model and its captive REIT (Standard Bearer), which owns and leases properties to its operating segments, providing a unique integrated real estate and healthcare platform. Currently, the investor narrative centers on Ensign's robust revenue growth, driven by acquisitions and organic expansion, alongside concerns about margin pressures from rising labor costs and regulatory changes in the skilled nursing industry. The stock has shown resilience with a 18.8% one-year gain, but recent volatility reflects debates over valuation sustainability and the impact of healthcare policy shifts.…

Bobby Quantitative Model
Aug 27, 2026

ENSG

The Ensign Group, Inc.

$173.54

-3.93%
Aug 27, 2026
Bobby Quantitative Model
The Ensign Group, Inc. is a leading provider of post-acute healthcare services in the United States, operating skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care facilities through its regional subsidiaries. The company distinguishes itself through a decentralized operating model and its captive REIT (Standard Bearer), which owns and leases properties to its operating segments, providing a unique integrated real estate and healthcare platform. Currently, the investor narrative centers on Ensign's robust revenue growth, driven by acquisitions and organic expansion, alongside concerns about margin pressures from rising labor costs and regulatory changes in the skilled nursing industry. The stock has shown resilience with a 18.8% one-year gain, but recent volatility reflects debates over valuation sustainability and the impact of healthcare policy shifts.

Related headlines

Bullish
ENSG Stock: Why It's Still a Buy for Investors

People also watch

HCA Healthcare

HCA Healthcare

HCA

Analysis
Tenet Healthcare

Tenet Healthcare

THC

Analysis
DaVita

DaVita

DVA

Analysis
Solventum

Solventum

SOLV

Analysis
Encompass Health

Encompass Health

EHC

Analysis

ENSG 12-Month Price Forecast

Historical Price
Current Price $173.54
Average Target $173.54
High Target $199.57
Low Target $147.51

Wall Street consensus

Most Wall Street analysts maintain a constructive view on The Ensign Group, Inc.'s 12-month outlook, with a consensus price target around $220.00 and implied upside of +26.8% versus the current price.

Average Target

$220.00

0 analysts

Implied Upside

+26.8%

vs. current price

Analyst Count

—

covering this stock

Price Range

$207 - $230

Analyst target range

The target price range spans from $207.00 (low) to $230.00 (high), with the average at $220.00. The high target of $230.00 suggests a potential 29.1% upside, likely assuming continued revenue growth and margin expansion. The low target of $207.00 still implies a 16.2% upside, indicating that even bearish analysts see value. The spread of $23.00 (11.1% of the average) is moderate, reflecting some uncertainty but overall conviction. The recent ratings actions show no downgrades, with Truist holding and others maintaining positive stances, reinforcing the bullish outlook.

Drowning in data?

Find the real signal!

Drowning in data?

Find the real signal!

ENSG Technical Analysis

The prevailing trend for ENSG is a recovery from a significant correction, with the stock currently trading at $178.16, up 18.77% over the past year but still 18.3% below its 52-week high of $218.00. The price sits at 71.4% of the 52-week range (from low of $141.58 to high of $218.00), indicating it has reclaimed a substantial portion of its losses but remains below prior peaks. This positioning suggests a mix of value opportunity and lingering overhead resistance, as the stock has not yet confirmed a full breakout.

Beta

0.69

0.69x market volatility

Max Drawdown

-31.8%

Largest decline past year

52-Week Range

$142-$218

Price range past year

Annual Return

+0.8%

Cumulative gain past year

PeriodENSG ReturnS&P 500
1m-5.2%+4.1%
3m+3.5%+1.9%
6m-19.0%+12.4%
1y+0.8%+19.3%
ytd-0.2%+13.1%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ENSG Fundamental Analysis

Ensign's revenue trajectory is robust, with Q1 2026 revenue of $1.389 billion, up 18.43% year-over-year, and sequential growth from $1.361 billion in Q4 2025 and $1.296 billion in Q3 2025. The growth is driven by the Skilled Services segment, which contributed $1.331 billion in revenue, while the Standard Bearer segment added $36.1 million. This consistent acceleration, with YoY growth rising from 14.8% in Q2 2025 to 18.4% in Q1 2026, indicates strong demand and successful acquisition integration, supporting the investment case for continued expansion.

Quarterly Revenue

$1.4B

2026-03

Revenue YoY Growth

+18.4%

YoY Comparison

Gross Margin

16.4%

Latest Quarter

Free Cash Flow

$406100000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Skilled Services Segment
Standard Bearer Segment

Open an Account, get $2 TSLA now!

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ENSG Overvalued?

Given Ensign's positive net income of $99.7 million in Q1 2026, the PE ratio is the appropriate primary valuation metric. The trailing PE stands at 29.03x, while the forward PE is 21.07x, implying the market expects significant earnings growth (a 27% forward contraction in multiple). This gap suggests investors are pricing in robust future EPS expansion, which aligns with the company's revenue growth trajectory. The PEG ratio of 2.06x indicates that the stock is not cheap relative to its growth rate, but it is not excessively overvalued either.

PE

29.0x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 17x~30x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

24.0x

Enterprise Value Multiple

Related headlines

Bullish
ENSG Stock: Why It's Still a Buy for Investors

People also watch

HCA Healthcare

HCA Healthcare

HCA

Analysis
Tenet Healthcare

Tenet Healthcare

THC

Analysis
DaVita

DaVita

DVA

Analysis
Solventum

Solventum

SOLV

Analysis
Encompass Health

Encompass Health

EHC

Analysis

Product

Partner

Markets

Stocks

© 2026 Flow AI Limited. All Rights Reserved.

Bobby, the world's first financial AI Agent, is developed by Flow AI, an AI-driven company. Flow AI is dedicated to providing global investors with AI-powered financial services across multiple markets.

Waffo.com Limited (authorised distributor): RM 1903, 19/F Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

Bobby
cs@bobby.ai
Bobby AI
RockFlow Platform
Stock Event
Macro Event
Industry Event
NVDA
AAPL
MSFT
AMZN
GOOG
META
TSLA
Privacy Policy
Terms of Use